[go: up one dir, main page]

MX2014008773A - Composiciones y metodos para el uso de ésteres de forbol. - Google Patents

Composiciones y metodos para el uso de ésteres de forbol.

Info

Publication number
MX2014008773A
MX2014008773A MX2014008773A MX2014008773A MX2014008773A MX 2014008773 A MX2014008773 A MX 2014008773A MX 2014008773 A MX2014008773 A MX 2014008773A MX 2014008773 A MX2014008773 A MX 2014008773A MX 2014008773 A MX2014008773 A MX 2014008773A
Authority
MX
Mexico
Prior art keywords
diseases
methods
forbol
chronic
compositions
Prior art date
Application number
MX2014008773A
Other languages
English (en)
Other versions
MX373291B (es
Inventor
Hung-Fong Chen
Zeng Tao Han
Original Assignee
Biosuccess Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosuccess Biotech Co Ltd filed Critical Biosuccess Biotech Co Ltd
Publication of MX2014008773A publication Critical patent/MX2014008773A/es
Publication of MX373291B publication Critical patent/MX373291B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

Métodos y composiciones que contienen ésteres de forbol o un derivado de un éster de forbol se provee para el tratamiento de enfermedades crónicas y agudas. Dichas condiciones pueden ser causadas por enfermedad, por síntomas o secuelas de la enfermedad. Enfermedades crónicas y agudas pueden deberse a infecciones virales como el VIH y el SIDA, enfermedades neoplásicas por infarto cerebral, enfermedades del riñón, incontinencia urinaria, desordenes autoinmunes, enfermedad de Parkinson, hipertrofia de la próstata, el envejecimiento, o el tratamiento de dichas enfermedades. Adicionalmente se proveen composiciones y métodos los cuales emplean ésteres de forbol o compuestos derivados en combinación con al menos un agente adicional para producir herramientas de tratamiento más eficaces contra las condiciones agudas y crónicas en sujetos mamíferos.
MX2014008773A 2012-01-18 2013-01-18 Composiciones y metodos para el uso de ésteres de forbol MX373291B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261588162P 2012-01-18 2012-01-18
US201261588167P 2012-01-18 2012-01-18
US201261588165P 2012-01-18 2012-01-18
PCT/US2013/022324 WO2013110006A2 (en) 2012-01-18 2013-01-18 Compositions and methods of use of phorbol esters

Publications (2)

Publication Number Publication Date
MX2014008773A true MX2014008773A (es) 2015-04-10
MX373291B MX373291B (es) 2020-05-06

Family

ID=48799818

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019011333A MX389510B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2018000468A MX395719B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol.
MX2014008776A MX370146B (es) 2012-01-18 2013-01-18 Composiciones y métodos para uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2014008773A MX373291B (es) 2012-01-18 2013-01-18 Composiciones y metodos para el uso de ésteres de forbol

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2019011333A MX389510B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.
MX2018000468A MX395719B (es) 2012-01-18 2013-01-18 Composiciones y métodos para el uso de ésteres de forbol.
MX2014008776A MX370146B (es) 2012-01-18 2013-01-18 Composiciones y métodos para uso de ésteres de forbol para el tratamiento de accidentes cerebrovasculares.

Country Status (18)

Country Link
US (1) US20170096386A1 (es)
EP (2) EP2804669B1 (es)
JP (5) JP6336914B2 (es)
KR (4) KR102102640B1 (es)
CN (4) CN104507466A (es)
AU (7) AU2013287280B2 (es)
BR (2) BR112014017650B1 (es)
CA (3) CA2861459C (es)
IL (2) IL233674B (es)
MX (4) MX389510B (es)
MY (5) MY176593A (es)
NZ (4) NZ726666A (es)
PH (10) PH12014501656B1 (es)
RU (3) RU2659684C2 (es)
SG (12) SG10201912642RA (es)
TW (6) TW201350111A (es)
WO (2) WO2013110006A2 (es)
ZA (3) ZA201405564B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008211081A1 (en) 2007-01-31 2008-08-07 Biosuccess Biotech Company Compositions and methods of use of phorbol esters
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
SG10201912642RA (en) * 2012-01-18 2020-02-27 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
NZ724799A (en) * 2014-04-16 2023-07-28 Sujon Pty Ltd Compositions and methods for the treatment or prevention of neurodegenerative disorders
JP2017527583A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患のプロストラチンによるターゲティング方法
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
WO2016122288A2 (ko) * 2015-01-30 2016-08-04 고려대학교산학협력단 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
KR20160107426A (ko) 2015-03-04 2016-09-19 임세영 구두 굽 및 그 제조방법
KR101710674B1 (ko) * 2015-07-22 2017-02-27 가톨릭대학교 산학협력단 Epo 수용체 및 pkc 동시 표적물질을 유효성분으로 포함하는 빈혈의 예방 또는 치료용 약학 조성물 및 이의 용도
CN106420687A (zh) * 2016-10-11 2017-02-22 孙君重 防护肠辐射损伤的方法及tpa的用途
KR102059160B1 (ko) * 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
CA3084139C (en) * 2017-11-15 2023-02-28 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
CN108689851B (zh) * 2018-05-28 2020-04-17 中山大学 一类惕各烷型二萜化合物及其制备方法和应用
WO2021062030A1 (en) * 2019-09-24 2021-04-01 K-Gen, Inc. Diterpenoid compounds that act on protein kinase c (pkc)
KR102541582B1 (ko) * 2020-10-29 2023-06-12 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
CN112715542A (zh) * 2021-01-20 2021-04-30 沈阳农业大学 巴豆烷二萜类化合物的制备方法及其在制备杀线虫的杀虫剂中的应用
CN116159126A (zh) * 2022-12-31 2023-05-26 山东大学齐鲁医院 同源二聚体介导的C/EBPαS16磷酸化通过液-液相分离调节急性髓系白血病分化

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375308A (en) 1942-08-21 1945-05-08 Ibm Method of making stencil cards
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US20070009529A1 (en) * 2002-03-26 2007-01-11 New York University Agents that dissolve arterial thrombi
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
CA2614110A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
AU2008211081A1 (en) * 2007-01-31 2008-08-07 Biosuccess Biotech Company Compositions and methods of use of phorbol esters
WO2009151496A2 (en) * 2008-03-26 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
EP2362770A4 (en) * 2008-11-21 2012-05-30 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE
RU2426535C2 (ru) * 2009-05-15 2011-08-20 Маргарита Алексеевна Морозова Применение бета-гидроксибутирата или его фармацевтически приемлемых солей для приготовления лекарственного средства, обладающего цитопротекторной активностью, включающей нейропротекторную, кардиопротекторную, противоишемическую, антигипоксическую, антистрессорную, актопротекторную и адаптогенную активности, лекарственное средство и способ профилактики, купирования и лечения с помощью этого лекарственного средства
US8575216B2 (en) * 2009-08-04 2013-11-05 Rutgers, The State University Of New Jersey Method of treatment for acute myelogenous leukemia
KR101144327B1 (ko) * 2010-04-02 2012-05-11 한국과학기술연구원 Ｐｋｃ 작용 활성제를 유효성분으로 함유하는 압상스 간질의 예방 및 치료용 조성물
SG10201912642RA (en) * 2012-01-18 2020-02-27 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters

Also Published As

Publication number Publication date
KR102102677B1 (ko) 2020-04-22
MY176593A (en) 2020-08-18
PH12020550760A1 (en) 2021-12-13
SG10201912676RA (en) 2020-02-27
HK1204447A1 (en) 2015-11-20
CA2861459A1 (en) 2013-07-25
TW202425963A (zh) 2024-07-01
MY199269A (en) 2023-10-24
IL233676A0 (en) 2014-08-31
SG10201902370QA (en) 2019-04-29
AU2020200954A1 (en) 2020-02-27
SG10201912677PA (en) 2020-02-27
RU2017140059A (ru) 2019-02-12
MY173042A (en) 2019-12-20
CA3077480C (en) 2023-03-14
KR20140117564A (ko) 2014-10-07
KR20140129000A (ko) 2014-11-06
MX2014008776A (es) 2015-08-20
PH12020550764A1 (en) 2021-08-16
PH12014501656A1 (en) 2014-10-13
NZ726666A (en) 2019-03-29
MY177300A (en) 2020-09-11
PH12020550768A1 (en) 2021-08-16
ZA201505443B (en) 2020-02-26
RU2650963C2 (ru) 2018-04-18
CN104507466A (zh) 2015-04-08
ZA201508059B (en) 2016-12-21
KR102102640B1 (ko) 2020-06-01
SG11201404212YA (en) 2014-10-30
CA2862301C (en) 2020-10-20
CN110025609A (zh) 2019-07-19
WO2014011209A1 (en) 2014-01-16
TW201934118A (zh) 2019-09-01
RU2018108884A3 (es) 2021-07-01
SG10201912642RA (en) 2020-02-27
BR112014017650A8 (pt) 2017-07-11
SG10201912674SA (en) 2020-03-30
SG10201912660UA (en) 2020-02-27
TW201350111A (zh) 2013-12-16
PH12020550755A1 (en) 2021-07-26
NZ727304A (en) 2018-08-31
PH12014501661A1 (en) 2014-10-20
NZ628294A (en) 2017-11-24
PH12020550765A1 (en) 2021-12-13
TWI666015B (zh) 2019-07-21
IL233674B (en) 2021-03-25
SG10201912649XA (en) 2020-02-27
CN108969514A (zh) 2018-12-11
AU2019210621A1 (en) 2019-08-22
RU2014133516A (ru) 2016-03-10
TWI817022B (zh) 2023-10-01
KR20200105731A (ko) 2020-09-08
ZA201405564B (en) 2016-02-24
IL233674A0 (en) 2014-08-31
JP2021073288A (ja) 2021-05-13
PH12014501656B1 (en) 2022-07-29
PH12020550762A1 (en) 2021-08-16
TWI664964B (zh) 2019-07-11
SG10201912667QA (en) 2020-02-27
MY192285A (en) 2022-08-17
AU2013287280B2 (en) 2016-06-30
SG10201912629UA (en) 2020-02-27
BR112014017650A2 (pt) 2021-06-08
TW201350110A (zh) 2013-12-16
TW202118485A (zh) 2021-05-16
WO2013110006A3 (en) 2015-02-05
AU2013209524A1 (en) 2014-08-14
EP2804669A4 (en) 2015-07-22
KR20190129073A (ko) 2019-11-19
JP2018203754A (ja) 2018-12-27
PH12020550759A1 (en) 2021-07-26
AU2020200954B2 (en) 2021-11-11
RU2659684C2 (ru) 2018-07-03
JP6715871B2 (ja) 2020-07-01
SG11201404211PA (en) 2014-09-26
RU2014133517A (ru) 2016-03-10
JP6835778B2 (ja) 2021-02-24
CA2862301A1 (en) 2014-01-16
CA3077480A1 (en) 2013-07-25
MX2019011333A (es) 2019-12-19
CA2861459C (en) 2020-08-25
BR112014017650B1 (pt) 2023-05-02
TW201817421A (zh) 2018-05-16
AU2013287280A1 (en) 2014-08-14
SG10201912653PA (en) 2020-02-27
AU2016203714B2 (en) 2018-01-04
JP2015513315A (ja) 2015-05-07
US20170096386A1 (en) 2017-04-06
TWI802707B (zh) 2023-05-21
EP2804601B1 (en) 2025-04-02
TW201804991A (zh) 2018-02-16
JP6463969B2 (ja) 2019-02-06
PH12020550752A1 (en) 2021-07-26
JP2015504096A (ja) 2015-02-05
CN104168957A (zh) 2014-11-26
EP2804669B1 (en) 2023-03-29
MX370146B (es) 2019-12-03
RU2017140059A3 (es) 2021-07-06
RU2018108884A (ru) 2019-02-26
EP2804601A4 (en) 2016-07-06
AU2016234887A1 (en) 2016-10-20
JP6336914B2 (ja) 2018-06-06
AU2019210621B2 (en) 2020-01-02
AU2016234887B2 (en) 2018-10-04
AU2016203714A1 (en) 2016-06-23
AU2017276345A1 (en) 2018-01-18
MX395719B (es) 2025-03-25
MX373291B (es) 2020-05-06
WO2013110006A2 (en) 2013-07-25
MX389510B (es) 2025-03-20
NZ628296A (en) 2017-02-24
HK1204461A1 (en) 2015-11-20
JP2018109014A (ja) 2018-07-12
NZ749356A (en) 2021-02-26
EP2804669A1 (en) 2014-11-26
EP2804601A2 (en) 2014-11-26
BR112014017716A8 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
MX2014008773A (es) Composiciones y metodos para el uso de ésteres de forbol.
BR112015021888A2 (pt) inibidores de dna-ik
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PH12016500953A1 (en) Tricyclic compounds as anticancer agents
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
WO2016048861A3 (en) Heterocyclic compounds and use thereof
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.

Legal Events

Date Code Title Description
FG Grant or registration